<DOC>
	<DOC>NCT00264147</DOC>
	<brief_summary>To assess the clinically active dose range of study medication in the treatment of patients with rheumatoid arthritis.</brief_summary>
	<brief_title>Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Patient with diagnosed rheumatoid arthritis (RA) for at least 6 months prior who is otherwise judged to be in general good health and who is currently taking nonsteroidal antiinflammatory drugs (NSAIDS) to treat his/her RA symptoms Patient will need to stop taking these medications in order to participate, but can continue taking his/her other antirheumatic medications as long as they have been stable for certain periods of time Patients with a disease or medical condition(s) that could worsen or interfere with the evaluation of the effectiveness of study medication are not allowed to participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Arcoxia</keyword>
</DOC>